Inovio Pharmaceuticals, Inc. (INO) Receives $20.20 Consensus Price Target from Analysts
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been given a consensus recommendation of “Hold” by the thirteen brokerages that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, three have given a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $20.20.
Several equities research analysts have weighed in on INO shares. HC Wainwright set a $13.00 price target on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, July 7th. Zacks Investment Research raised shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 target price for the company in a research report on Tuesday, July 11th. Aegis reissued a “buy” rating and set a $14.00 target price on shares of Inovio Pharmaceuticals in a research report on Tuesday, July 18th. BidaskClub downgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Finally, Maxim Group set a $12.00 target price on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 9th.
Shares of Inovio Pharmaceuticals (NASDAQ:INO) traded down 0.32% during trading on Wednesday, reaching $6.23. 869,299 shares of the company were exchanged. The firm’s market cap is $562.11 million. Inovio Pharmaceuticals has a 52-week low of $5.28 and a 52-week high of $9.86. The stock’s 50-day moving average is $6.22 and its 200-day moving average is $6.64.
Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.08. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. The firm had revenue of $20.41 million during the quarter, compared to the consensus estimate of $16.29 million. During the same period in the previous year, the firm posted ($0.26) earnings per share. The business’s revenue was up 229.2% compared to the same quarter last year. Equities research analysts predict that Inovio Pharmaceuticals will post ($0.95) earnings per share for the current fiscal year.
WARNING: “Inovio Pharmaceuticals, Inc. (INO) Receives $20.20 Consensus Price Target from Analysts” was first posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.dailypolitical.com/2017/10/21/inovio-pharmaceuticals-inc-ino-receives-20-20-consensus-price-target-from-analysts.html.
Several large investors have recently bought and sold shares of the company. BlueCrest Capital Management Ltd purchased a new position in Inovio Pharmaceuticals during the second quarter worth about $107,000. PNC Financial Services Group Inc. boosted its holdings in Inovio Pharmaceuticals by 5.0% during the second quarter. PNC Financial Services Group Inc. now owns 21,000 shares of the biopharmaceutical company’s stock worth $164,000 after purchasing an additional 1,000 shares during the last quarter. Northwestern Mutual Wealth Management Co. purchased a new position in Inovio Pharmaceuticals during the second quarter worth about $171,000. OxFORD Asset Management LLP purchased a new position in Inovio Pharmaceuticals during the second quarter worth about $194,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Inovio Pharmaceuticals during the second quarter worth about $197,000. 24.83% of the stock is owned by institutional investors.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.